NADAC Pricing Lookup
& Drug Pricing Database
Search weekly CMS NADAC prices by drug name or NDC, then analyze market, manufacturer, and class-level trends.
- Published NDCs
- 30,211
- Price increases
- 15,052
- Price decreases
- 13,763
- Unchanged prices
- 1,296
NADAC Update: Biologic Price Relief Offsets Broad-Based Generic Increases
The November 18, 2026 NADAC release reflects a near-balanced market with 15,052 price increases against 13,763 decreases across 30,111 comparable NDCs, though dollar-weighted impact skews toward relief in high-cost specialty categories. The Interleukin-23 Antagonist class posted the largest aggregate price pressure at -$1.5M, driven primarily by risankizumab-rzaa, while AbbVie Inc. recorded the largest manufacturer-level decline (-$837.4K) across 64 products. Partially offsetting this, Risperidone saw a +3.5% average increase across 114 NDCs, contributing $677.1K in added cost, and broad-based Corticosteroid movement (1,102 drugs) remained modest despite its scale.
Key takeaways
- Price activity was nearly even (15,052 increases vs. 13,763 decreases), indicating no dominant market-wide directional trend this week.
- High-impact declines were concentrated in specialty and GLP-1 categories: Interleukin-23 Antagonist (-$1.5M), Opioid Antagonist (-$1.1M), and GLP-1 Receptor Agonist (-$922.3K) led dollar-weighted relief.
- Generic breadth drove notable cost pressure, with Risperidone (+3.5%, 114 NDCs) and broad Corticosteroid movement (1,102 drugs) signaling sustained upward pressure outside specialty tiers.
What to watch
Naloxone Hydrochloride Pricing Shift
A -6.8% average move across 20 NDCs produced a -$986.8K impact, with Padagis Israel Pharmaceuticals products (including a -7.4% NDC-level decline) contributing significantly; payers should monitor formulary cost basis for opioid antagonists.
GLP-1 and Liraglutide Volatility
Liraglutide fell -8.0% across 12 NDCs (-$641.6K), part of a broader -$922.3K decline in the GLP-1 Receptor Agonist class; procurement teams should reassess contract pricing assumptions given continued downward momentum.
Interleukin-23 Antagonist Concentration Risk
Despite covering only 4 drugs, this class drove the largest weighted impact (-$1.5M), led by risankizumab-rzaa (-$739.6K across 2 NDCs) and AbbVie's broader -$837.4K swing; limited breadth means pricing shifts here can materially affect specialty drug budgets.
Market Signals
Latest 7-day price movements across drug markets, manufacturers, and therapeutic classes.
Drug Market Movers
PREDNISOLONE SODIUM PHOSPHATE
7 manufacturers
METHAMPHETAMINE HYDROCHLORIDE
2 manufacturers
FLUPHENAZINE HYDROCHLORIDE
17 manufacturers
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE
1 manufacturers
Manufacturer Activity
U.S. Pharmaceutical Corporation
Oryza Pharmaceuticals Inc.
Beach Products, Inc.
International Medication Systems, Limited
Therapeutic Class Watch
Glycopeptide Antibacterial
Vitamin K
Warfarin Reversal Agent
Endothelin Receptor Antagonist
Learn About NADAC Pricing
Explore guides and resources to understand drug pricing, access our comprehensive database, and track pharmaceutical market trends.
What is NADAC Pricing?
Complete guide to NADAC pricing, how it works, and why it matters for pharmaceutical reimbursement and market analysis.
Evaluating a Pricing Database
Learn what to look for in a pharmaceutical pricing database for reimbursement analysis and sourcing decisions.
Drug Pricing Database Guide
Learn how to search prescription drug prices by NDC, generic name, manufacturer, and therapeutic class using NADAC data.